SG11201503697TA - Treatment of pulmonary disease - Google Patents

Treatment of pulmonary disease

Info

Publication number
SG11201503697TA
SG11201503697TA SG11201503697TA SG11201503697TA SG11201503697TA SG 11201503697T A SG11201503697T A SG 11201503697TA SG 11201503697T A SG11201503697T A SG 11201503697TA SG 11201503697T A SG11201503697T A SG 11201503697TA SG 11201503697T A SG11201503697T A SG 11201503697TA
Authority
SG
Singapore
Prior art keywords
treatment
pulmonary disease
pulmonary
disease
Prior art date
Application number
SG11201503697TA
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503697T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of SG11201503697TA publication Critical patent/SG11201503697TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SG11201503697TA 2012-11-28 2013-11-26 Treatment of pulmonary disease SG11201503697TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
SG11201503697TA true SG11201503697TA (en) 2015-06-29

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503697TA SG11201503697TA (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Country Status (19)

Country Link
US (3) US20140148428A1 (ru)
EP (1) EP2925328A1 (ru)
JP (1) JP6270171B2 (ru)
KR (1) KR102106186B1 (ru)
CN (1) CN104853758A (ru)
AU (1) AU2013352288B2 (ru)
BR (1) BR112015012312A2 (ru)
CA (1) CA2891348C (ru)
CL (1) CL2015001442A1 (ru)
HK (1) HK1211844A1 (ru)
IL (1) IL239025B (ru)
MX (1) MX2015006710A (ru)
MY (1) MY170802A (ru)
NZ (1) NZ708501A (ru)
PH (1) PH12015501108B1 (ru)
RU (1) RU2693382C2 (ru)
SG (1) SG11201503697TA (ru)
TW (1) TWI636786B (ru)
WO (1) WO2014085474A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
EP3221332B1 (en) * 2014-11-19 2019-04-24 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CA2968309A1 (en) * 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
MX2017006565A (es) * 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
US20170327531A1 (en) * 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
US11072631B2 (en) * 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
US11034717B2 (en) * 2015-10-07 2021-06-15 Intercept Pharmaceuticals, Inc. Farnesoid X receptor modulators
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
EP3414256B1 (en) 2016-02-10 2022-01-19 Dr. Reddy's Laboratories Limited Purification process involving amine salt of obeticholic acid
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
JP6968821B2 (ja) * 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017208165A1 (en) * 2016-06-01 2017-12-07 Dr. Reddy’S Laboratories Limited Process for preparation of obeticholic acid
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
WO2018064441A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
US11111265B2 (en) * 2017-11-02 2021-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
EP3827008A1 (en) 2018-07-25 2021-06-02 Novartis AG Nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR79615B (ru) 1982-10-08 1984-10-31 Glaxo Group Ltd
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
CA2213442A1 (en) 1995-03-10 1996-09-19 The Minnesota Mining & Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
JP4021327B2 (ja) * 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
WO2005032549A1 (en) * 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
DK2712617T3 (en) * 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
SI2040713T1 (sl) * 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
WO2008000643A1 (en) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
WO2010014836A2 (en) * 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
ES2592452T3 (es) * 2008-11-19 2016-11-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y métodos de uso de los mismos
US20110257139A1 (en) * 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
JP5909774B2 (ja) * 2009-08-25 2016-04-27 クィン ビル セラピューティクス インコーポレイテッド 胆道疾患を治療するためのポリヒドロキシル化胆汁酸
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN104781272A (zh) * 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式

Also Published As

Publication number Publication date
AU2013352288A1 (en) 2015-06-04
TWI636786B (zh) 2018-10-01
HK1211844A1 (en) 2016-06-03
KR20150089052A (ko) 2015-08-04
NZ708501A (en) 2019-03-29
EP2925328A1 (en) 2015-10-07
US20180064729A1 (en) 2018-03-08
AU2013352288B2 (en) 2017-11-23
CN104853758A (zh) 2015-08-19
CA2891348C (en) 2020-04-28
KR102106186B1 (ko) 2020-05-04
JP6270171B2 (ja) 2018-01-31
MY170802A (en) 2019-08-28
CA2891348A1 (en) 2014-06-05
IL239025B (en) 2021-04-29
RU2015122027A (ru) 2017-01-10
BR112015012312A2 (pt) 2017-07-11
US20140148428A1 (en) 2014-05-29
PH12015501108A1 (en) 2015-08-17
US20160213689A1 (en) 2016-07-28
PH12015501108B1 (en) 2015-08-17
JP2016500111A (ja) 2016-01-07
MX2015006710A (es) 2016-01-15
IL239025A0 (en) 2015-07-30
RU2693382C2 (ru) 2019-07-02
WO2014085474A1 (en) 2014-06-05
CL2015001442A1 (es) 2015-08-28
TW201434469A (zh) 2014-09-16

Similar Documents

Publication Publication Date Title
HK1211844A1 (en) Treatment of pulmonary disease
HK1201452A1 (en) Methods of reducing risk of cardiovascular disease
EP2890418A4 (en) VENTRICULAR CUFF
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HK1200348A1 (en) Methods and materials for treatment of pompes disease
ZA201406082B (en) Use of ccr3-inhibitors
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2704723A4 (en) TREATMENT OF POLYCYSTIC DISEASES
IL234606B (en) Innovative methods and compounds for the treatment of diseases
HK1211213A1 (en) Treatment of diseases involving mucin
EP2900259A4 (en) GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES
ZA201501038B (en) Treatment of wax
GB201312378D0 (en) Structure of shoe
GB201207907D0 (en) Treatment of depression
GB201204645D0 (en) Treatment of disease
GB201219092D0 (en) Treatment of cardiovascular disease
GB201201778D0 (en) Treatment of inflammatory respiratory disease
EP2911662A4 (en) METHOD OF TREATING A DISEASE
GB201320014D0 (en) Treatment of cardiovascular disease
GB201321628D0 (en) Treatment of disease
GB201118269D0 (en) Treatment of cardiovascular disease
GB201107988D0 (en) Treatment of cardiovascular disease
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment